Ovid Therapeutics Appoints Barbara G. Duncan to its Board of Directors
June 14 2017 - 4:30PM
Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company
committed to developing medicines for patients with rare
neurological disorders, today announced the appointment of Barbara
G. Duncan to the company’s board of directors, where she will serve
as chairperson of the Audit Committee.
“Ovid is assembling a diversified, independent and very strong
board of directors. Barbara’s expertise will add to and complement
the capabilities of our current board in key areas,” said Jeremy
Levin, D.Phil, MB Chir, chairman of the board of directors and
chief executive officer of Ovid. “Barbara has served on both public
and private biotechnology company boards and has deep financial and
operating experience, which will be invaluable as we transition
into a public company and continue to execute our strategy to
become a leading neurology company. I would like to welcome her to
our board of directors.”
“With the recent IPO, pipeline expansion and clinical trial
initiations, this is a pivotal time for Ovid. I am excited to join
the team during such an important phase for a growing company,”
said Ms. Duncan. “I look forward to working closely with the team
to further Ovid’s mission of developing impactful medicines that
transform the lives of patients and their families living with rare
neurological disorders.”
Ms. Duncan previously served as the chief financial officer and
treasurer at Intercept Pharmaceuticals, Inc. Prior to Intercept,
Ms. Duncan held various senior leadership roles of increasing
responsibility at DOV Pharmaceutical, Inc., including chief
financial officer and ultimately serving as chief executive officer
prior to DOV’s sale to Euthymics Bioscience, Inc. in 2010. Ms.
Duncan has also held roles in the corporate finance groups at SBC
Warburg Dillon Read, Inc. and Lehman Brothers, Inc. She currently
serves on the board of Aevi Genomic Medicine, Inc., Jounce
Therapeutics, Inc., Adaptimmune Therapeutics plc, Innoviva, Inc.
and ObsEva SA. Ms. Duncan received a master’s of business
administration from the Wharton School of the University of
Pennsylvania and a bachelor of business administration from
Louisiana State University.
About Ovid TherapeuticsOvid Therapeutics
(NASDAQ:OVID) is a New York-based, biopharmaceutical company using
its BoldMedicine™ approach to develop therapies that transform the
lives of patients with rare neurological disorders. Ovid’s drug
candidate, OV101, is currently in development for the treatment of
Angelman syndrome and Fragile X syndrome. Ovid has initiated the
Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a
Phase 1 trial in adolescents with Angelman syndrome or Fragile X
syndrome. Ovid is also developing OV935 in collaboration with
Takeda Pharmaceutical Company Limited for the treatment of rare
epileptic encephalopathies. Ovid expects to initiate a Phase 1b/2a
trial of OV935 to treat rare epileptic encephalopathies in
2017.
For more information on Ovid, please visit
http://www.ovidrx.com/.
Forward-Looking Statements
This press release includes certain disclosures which contain
“forward-looking statements,” including, without limitation,
statements regarding the timing of initiating a Phase 1b/2a trial
of OV935 to treat rare epileptic encephalopathies. You can identify
forward-looking statements because they contain words such as
“will,” “believes” and “expects.” Forward-looking statements are
based on Ovid’s current expectations and assumptions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
may differ materially from those contemplated by the
forward-looking statements, which are neither statements of
historical fact nor guarantees or assurances of future performance.
Important factors that could cause actual results to differ
materially from those in the forward-looking statements are set
forth in Ovid’s filings with the Securities and Exchange
Commission, including its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2017, under the caption “Risk Factors.”
Ovid assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
Contacts
Investors:
Burns McClellan
Steve Klass, 212-213-0006
Sklass@burnsmc.com
Media:
Pure Communications, Inc.
Katie Engleman, 910-509-3977
katie@purecommunicationsinc.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2023 to Apr 2024